Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 15/20 | 0.72 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.72 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.72 |
| ▸ | MAPK13 | O15264 | 12/20 | 0.69 |
| ▸ | MAPK12 | P53778 | 12/20 | 0.69 |
| ▸ | MAPK11 | Q15759 | 12/20 | 0.69 |
| ▸ | GCGR | P47871 | 11/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.67 |
| ▸ | FRK | P42685 | 2/20 | 0.67 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.67 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.67 |
| ▸ | GSK3B | P49841 | 2/20 | 0.67 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.67 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.67 |
| ▸ | LCK | P06239 | 1/20 | 0.67 |
| ▸ | RET | P07949 | 1/20 | 0.67 |
| ▸ | PRKACA | P17612 | 1/20 | 0.67 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17002223 | 0.84 | MAPK14 (0.77) | ALOX5MAPK14CSNK1DCSNK1EMAPK13 | |
| SCHEMBL30197605 | 0.84 | MAPK14 (1.00) | ALOX5MAPK14CSNK1DCSNK1EMAPK13 | |
| SCHEMBL17002317 | 0.84 | MAPK14 (1.00) | ALOX5MAPK14CSNK1DCSNK1EMAPK13 | |
| SCHEMBL14648344 | 0.83 | ALOX5 (0.70) | ALOX5MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6449484 | 0.82 | MAPK14 (0.73) | ALOX5MAPK14CSNK1DCSNK1EMAPK13 | |
| SCHEMBL6450700 | 0.81 | MAPK14 (0.77) | ALOX5MAPK14CSNK1DCSNK1EMAPK13 | |
| SCHEMBL4563107 | 0.81 | ALOX5 (1.00) | ALOX5MAPK14CSNK1DCSNK1EMAPK13 | |
| SCHEMBL17002225 | 0.81 | MAPK14 (0.77) | ALOX5MAPK14CSNK1DCSNK1EMAPK13 | |
| SCHEMBL6003680 | 0.81 | MAPK14 (1.00) | ALOX5MAPK14CSNK1DCSNK1EMAPK13 | |
| SCHEMBL2650029 | 0.81 | MAPK14 (1.00) | ALOX5MAPK14CSNK1DCSNK1EMAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0889887-A4 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORP (US) | 2003-06-11 | — | — | EP | claimed |
| US-20030064997-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-03 | — | — | US | claimed |
| US-6235760-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS | SMITHKLINE BEECHAM CORPORATION | 2001-05-22 | — | — | US | claimed |
| EP-0906099-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2001-02-07 | — | — | EP | claimed |
| EP-0906099-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 1999-04-07 | — | — | EP | claimed |
| EP-0889887-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-13 | — | — | EP | claimed |
| WO-1997036587-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | claimed |
| WO-1997035855-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-02 | — | — | WO | claimed |
| JP-H09500137-A | — | — | 1997-01-07 | — | — | JP | claimed |
| EP-0708768-A4 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORP (US) | 1996-08-21 | — | — | EP | claimed |
| EP-0708768-A1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-05-01 | — | — | EP | claimed |
| WO-1995002591-A1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-01-26 | — | — | WO | claimed |
| EP-1539121-A4 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1545535-A4 | TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE | SCIOS INC (US) | 2008-06-04 | — | — | EP | disclosed |
| EP-1583535-A4 | METHODS FOR TREATING DIABETES | SCIOS INC (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1583535-A2 | METHODS FOR TREATING DIABETES | SCIOS INC. (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-0708768-A4 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORP (US) | 1996-08-21 | — | — | EP | disclosed |
| EP-0708768-A1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995003297-A1 | IMIDAZOLES FOR TREATING CYTOKINE MEDIATED DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-02 | — | — | WO | disclosed |
| WO-1995002591-A1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064997-A1 | Novel compounds | BRD4, BRDT, HDAC6 | ALOX5 2555/4885MAPK14 3769/4885CSNK1D 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.